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Abstract
Background: Cardiovascular disease (CVD) and its most common manifestations – including coronary heart disease
(CHD), stroke, heart failure (HF), and atrial fibrillation (AF) – are major causes of morbidity and mortality. In many
industrialized countries, cardiovascular disease (CVD) claims more lives each year than any other disease. Heart disease
and stroke are the first and third leading causes of death in the United States. Prior investigations have reported several
single gene variants associated with CHD, stroke, HF, and AF. We report a community-based genome-wide association
study of major CVD outcomes.
Methods: In 1345 Framingham Heart Study participants from the largest 310 pedigrees (54% women, mean age 33 years
at entry), we analyzed associations of 70,987 qualifying SNPs (Affymetrix 100K GeneChip) to four major CVD outcomes:
major atherosclerotic CVD (n = 142; myocardial infarction, stroke, CHD death), major CHD (n = 118; myocardial
infarction, CHD death), AF (n = 151), and HF (n = 73). Participants free of the condition at entry were included in
proportional hazards models. We analyzed model-based deviance residuals using generalized estimating equations to test
associations between SNP genotypes and traits in additive genetic models restricted to autosomal SNPs with minor allele
frequency ≥0.10, genotype call rate ≥0.80, and Hardy-Weinberg equilibrium p-value ≥ 0.001.
Results: Six associations yielded p < 10-5. The lowest p-values for each CVD trait were as follows: major CVD, rs499818,
p = 6.6 × 10-6; major CHD, rs2549513, p = 9.7 × 10-6; AF, rs958546, p = 4.8 × 10-6; HF: rs740363, p = 8.8 × 10-6. Of
note, we found associations of a 13 Kb region on chromosome 9p21 with major CVD (p 1.7 – 1.9 × 10-5) and major
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Also, rs10501920 in CNTN5 was associated with AF (p = 9.4 × 10-6) and HF (p = 1.2 × 10-4). Complete results for these
phenotypes can be found at the dbgap website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
Conclusion: No association attained genome-wide significance, but several intriguing findings emerged. Notably, we
replicated associations of chromosome 9p21 with major CVD. Additional studies are needed to validate these results.
Finding genetic variants associated with CVD may point to novel disease pathways and identify potential targeted
preventive therapies.
Background
Cardiovascular disease (CVD) and its most common
manifestations, coronary heart disease (CHD), stroke,
heart failure (HF), and atrial fibrillation (AF) are major
causes of morbidity and mortality. In many industrialized
countries CVD claims more lives each year than any other
disease. In the United States, for example, heart disease
and stroke are the first and third leading causes of death
[1]. At age 40 the lifetime risk of developing CHD is one
in two for men and one in three for women [2], the life-
time risk for stroke is one in six for men and one in five for
women [3], the lifetime risk for HF is one in five in men
and women [4] and the lifetime risk for AF is one in four
in both sexes [5].
Prior Framingham Heart Study research points to strong
familial patterns of CVD, HF, and AF [6-8] and such evi-
dence is consistent with a genetic effect. Several single
gene variants associated with CHD and atherosclerotic
CVD have been reported [9-13]. A substantial body of
research has also identified a number of genetic variants
associated with HF and AF [14,15].
We report results of a genome-wide association study of
four CVD outcomes in community-based Framingham
Heart Study participants who were enrolled without
regard to disease status. Analysis for each specific outcome
was restricted to those free of the condition at baseline.
We also provide association results for previously
reported candidate genes and candidate regions for these
CVD outcomes.
Methods
Study sample
In 1948, 5209 men and women from Framingham, Mas-
sachusetts, who were between 28 and 62 years of age, were
recruited to participate in the Framingham Heart Study
[16]. Periodic clinic visits, performed every two years,
included a medical history, physical examination focus-
ing on the cardiovascular system, laboratory tests, and
electrocardiogram. The offspring cohort of the Framing-
ham Heart Study began in 1971, with the enrollment of
5124 offspring and spouses of offspring of original partic-
ipants [17]. Repeated examinations of the offspring
cohort occurred approximately every 4 years, except for an
8 year interval between their initial and second visit. At
each clinic visit, participants gave written informed con-
sent. The consent documents and the examination con-
tent were approved by the Institutional Review Board at
Boston University Medical Center (Boston, Massachu-
setts).
Phenotype definition & methods
All participants in both cohorts who were free of a specific
condition at enrollment were analyzed for onset of that
endpoint during follow up through the end of 2004. All
suspected CVD events were reviewed and adjudicated by a
panel of three Framingham physician investigators after
review of all available Framingham Heart Study examina-
tion records, hospitalization records, and physician notes,
using previously published criteria [18].
For these analyses, we considered four groups of events:
major CHD events included recognized myocardial inf-
arction, coronary insufficiency, and death due to CHD;
major atherosclerotic CVD events included major CHD
plus atherothrombotic stroke; the remaining groups were
HF and AF. Myocardial infarction was diagnosed by the
presence of 2 out of 3 clinical criteria: new diagnostic Q-
waves on ECG, prolonged ischemic chest discomfort, and
elevation of serum biomarkers of myocardial necrosis.
CHD death was established upon review of all available
records, if the cause of death was probably CHD and no
other cause could be ascribed.
Atherothrombotic brain infarction was defined as a non-
embolic acute-onset focal neurological deficit of vascular
etiology that persisted for more than 24 hours or an
ischemic infarct was documented at autopsy.
History of interim hospitalizations and symptoms of HF
were obtained at each clinic examination; outside medical
records were evaluated for participants who did not attend
an examination. Three physicians reviewed all suspected
interim events using Framingham Heart Study clinic
notes, external physician reports and hospitalization
records. HF was diagnosed when at least two major crite-
ria were present, or one major and two minor criteria.
Major criteria were paroxysmal nocturnal dyspnea, pul-
monary rales, distended jugular veins, enlarging heart sizePage 2 of 9
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jugular reflux, third heart sound, jugular venous pressure
of 16 cm or greater, weight loss of 4.5 kg or greater in
response to diuresis, pulmonary edema, visceral conges-
tion, or cardiomegaly on autopsy. Minor criteria counted
only if not attributed to another disease. Minor criteria
were bilateral ankle edema, nocturnal cough, shortness of
breath on ordinary exertion, hepatomegaly, pleural effu-
sion, vital capacity decreased by one third from previous
maximum, and heart rate ≥120 beats/min.
AF was diagnosed when, upon review by a study cardiolo-
gist, AF or atrial flutter was present on an ECG obtained
from a routine Framingham clinic examination or from a
hospital or physician record. HF was defined on the basis
of review of medical records and the finding of concurrent
presence of two major or one major plus two minor crite-
ria [19].
Genotyping methods
The accompanying Overview [20] provides details of the
genotyping methods used in this investigation. The
Affymetrix 100K chip with 112,990 autosomal SNPs was
used to genotype individual participant DNA on the
Framingham Heart Study family plate set. SNPs were
excluded for minor allele frequency < 0.1 (n = 38062); call
rate < 0.8 (n = 2346); Hardy Weinberg equilibrium p
value < 0.001 (n = 1595). After these exclusions, 70,987
SNPs were available for analysis.
Statistical methods
Proportional-hazards models were used to analyze time
to each endpoint, stratified by cohort, using covariate val-
ues obtained at enrollment. Models were adjusted for (i)
sex and age, or (ii) sex, age and multiple covariates. For
CVD and CHD, covariates included smoking, diabetes,
systolic BP, anti-hypertensive treatment and total choles-
terol; for HF, covariates were smoking, diabetes, systolic
BP, anti-hypertensive treatment and body mass index; for
AF, covariates were diabetes, systolic BP, anti-hypertensive
therapy and valve disease. Deviance residuals estimated
from each model were standardized (mean 0, variance 1)
to form the phenotypes analyzed with genetic models. For
genotype-phenotype association analyses, we assumed an
additive-allele model of inheritance and we conducted
association tests using regression models with generalized
estimating equations (GEE), as well as family-based asso-
ciation testing using FBAT. Due to relatively small num-
bers of outcome events and non-normality of the
deviance residuals, we decided a priori not to perform
linkage analysis on outcomes residuals. The distribution
of observed p values for the four CVD outcomes was com-
pared to that which would be expected under the null
hypothesis of no genetic associations with outcomes.
Candidate gene analyses
GEE and FBAT additive genetic effect models also were
run for SNPs in or near candidate genes for each of the
CVD outcomes. Candidate genes were selected after sepa-
rate literature searches for each outcome. All SNPs across
the interval extending from 200 Kb proximal to the start
to 200 kb beyond the end of each gene were eligible if the
minor allele frequency was ≥0.1, the genotype call rate
was ≥0.8, and the Hardy-Weinberg equilibrium p value
was ≥0.001.
Results
Four primary phenotypes were analyzed: major athero-
sclerotic CVD (n = 142), major CHD (n = 118), HF (n =
73), and AF (n = 151). Covariates for each outcome are
listed in Table 1. In this sample, deviance residuals from
multivariable models generally had low heritability: HF,
0.023 (SE = 0.054); Major CVD, 0.036 (SE = 0.058), Major
CHD, 0.085 (SE = 0.061); and AF, 0.135 (SE = 0.058).
GEE additive genetic models yielded six associations with
p values < 10-5 and another 31 with p values < 10-4 (see
Table 2a for best 25). The lowest p-values for each CVD
phenotype were as follows: major CVD, rs499818, p = 6.6
× 10-6; major CHD, rs2549513, p = 9.7 × 10-6; AF,
rs958546, p = 4.8 × 10-6; HF: rs740363, p = 8.8 × 10-6. Of
note, rs10501920 in CNTN5 was associated with AF (p =
9.4 × 10-6) and HF (p = 1.2 × 10-4). Three SNPs near
PHACTR1 were associated with major CVD (rs499818,
rs1512411, rs507369; lowest p = 6.6 × 10-6) and one of
these was associated with major CHD (rs1512411; 
Table 1: Phenotype definitions
Phenotype Definition Number of individuals Number with event Adjustment*
Major CVD Myocardial infarction, coronary 
insufficiency, CHD death, or 
atherothrombotic stroke
1345 142 Age, sex; Multivariable: Age, sex, smoking, diabetes, 
systolic BP, anti-hypertensive therapy, total 
cholesterol
Major CHD Myocardial infarction, coronary 
insufficiency, or CHD death
1345 118 Same as Major CVD
Heart failure Heart failure, hospitalized or non-
hospitalized
1345 73 Same as Major CVD except BMI added, total 
cholesterol removed
Atrial fibrillation Atrial fibrillation or atrial flutter on ECG 1341 151 Age, sex; Multivariable: Age, sex, diabetes, systolic 
BP, anti-hypertensive therapy, valve disease
* Covariates in cohort-stratified proportional-hazards models for time to eventPage 3 of 9
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Table 2: Additive Genetic Model – ordered by GEE (2a) and FBAT (2b) p-value Results
Phenotype SNP Chromosome Position GEE P value FBAT P value Gene
2a. Results ordered by GEE p-value results
AF rs958546 13 45,731,718 4.78E-06 0.104
Major CVD rs499818 6 13,440,446 6.64E-06 0.17
AF rs4776472 15 67,793,927 7.87E-06 0.042
HF rs740363 10 118,565,596 8.82E-06 0.065 KIAA1598
AF rs10501920 11 98,998,383 9.40E-06 0.448 CNTN5
Major CHD rs2549513 16 78,108,228 9.65E-06 0.106
AF rs10507539 13 45,732,707 1.05E-05 0.02
Major CVD rs1512411 6 13,439,076 1.55E-05 0.366 PHACTR1, TBC1D7
Major CVD rs10511701 9 22,102,599 1.67E-05 0.132
Major CVD rs1556516 9 22,090,176 1.86E-05 0.071
Major CVD rs1537371 9 22,089,568 1.87E-05 0.068
Major CHD rs10497726 2 192,876,826 1.98E-05 0.046 TMEFF2
Major CHD rs2962994 15 55,129,991 1.98E-05 0.279 TCF12
Major CHD rs997651 17 61,344,845 2.28E-05 0.547 MGC33887
Major CVD rs2148079 13 109,989,414 2.33E-05 0.026 RAB20
AF rs10501918 11 98,971,412 2.40E-05 0.093 CNTN5
HF rs10511633 9 17,151,527 2.59E-05 0.044 C9orf39
Major CHD rs7836535 8 96,774,748 2.63E-05 0.003
Major CHD rs1820996 15 55,120,501 2.83E-05 0.218 TCF12
Major CHD rs213168 15 55,028,949 3.09E-05 0.278 TCF12
Major CHD rs997652 17 61,344,827 3.22E-05 0.613 MGC33887
AF rs4590838 11 97,372,875 4.03E-05 0.248
Major CHD rs10516882 4 92,265,754 4.33E-05 0.858
Major CVD rs1742083 14 90,256,423 5.23E-05 0.138 TTC7B
Major CVD rs507369 6 13,440,039 6.23E-05 0.137 PHACTR1, TBC1D7
2b. Results Ordered by FBAT
Major CHD rs10505879 12 22,539,123 0.058 3.06E-05 KIAA0528
Major CVD rs39312 7 116,548,736 0.138 4.37E-05 WNT2
AF rs10511311 3 113,538,529 0.003 4.45E-05 CD200
AF rs1427828 12 88,264,967 0.018 4.58E-05 DUSP6
HF rs10515869 5 163,444,804 0.029 4.72E-05
AF rs1751382 14 67,762,403 0.138 5.14E-05 RAD51L1
AF rs1314913 14 67,769,347 0.126 5.53E-05 RAD51L1
AF rs262467 6 120,497,469 0.117 6.39E-05
AF rs412253 4 31,119,019 0.086 6.55E-05
Major CVD rs39317 7 116,560,255 0.219 6.72E-05 WNT2, ASZ1
Major CVD rs9886209 7 116,599,175 0.594 6.95E-05 ASZ1
Major CVD rs10493900 1 98,357,234 0.801 7.10E-05
AF rs1298340 14 67,747,245 0.275 7.40E-05 RAD51L1
Major CVD rs2452503 10 60,686,639 0.384 9.94E-05 FAM13C1
AF rs324735 4 77,062,193 0.018 9.98E-05
Major CHD rs580069 11 121,794,555 0.074 1.24E-04
AF rs1604355 1 187,190,664 0.294 1.29E-04 FAM5C
Major CHD rs559453 11 121,794,482 0.073 1.32E-04
Major CHD rs951442 15 31,705,234 0.003 1.35E-04 RYR3
HF rs1176486 10 132,315,529 0.165 1.49E-04
AF rs2421954 2 63,665,926 0.003 1.51E-04 LOC51057
HF rs9313999 5 163,444,569 0.015 1.55E-04
AF rs7676376 4 158,199,764 0.282 1.72E-04 PDGFC
Major CHD rs10501127 11 33,698,233 0.251 1.78E-04 CD59
AF rs1163397 3 110,400,929 0.002 1.78E-04
BMC Medical Genetics 2007, 8(Suppl 1):S5 http://www.biomedcentral.com/1471-2350/8/S1/S5p = 6.3 × 10-5). Among GEE results for HF was rs939698
(p = 3.6 × 10-4) in RYR2, which has been implicated in
arrhythmogenic right ventricular dysplasia/cardiomyopa-
thy [21], a rare familiar cardiomyopathy.
Results of FBAT are provided in Table 2b. The lowest p val-
ues for each phenotype were: major CVD, rs39312 in
WNT2, p = 4.4 × 10-5; major CHD, rs10505879, p = 3.1 ×
10-5; AF, rs10511311 in CD200, p = 4.5 × 10-5; and HF,
rs10515869, 4.72 × 10-5.
The distribution of observed GEE p values is presented in
Table 3. Note that the ratio of observed to expected num-
bers is inflated only at very low p values.
Association results for 408 SNPs in 46 candidate genes
(Table 4) revealed suggestive evidence for major CHD
events for ALOX5AP (23 SNPs, 7 with p < 0.05 by GEE or
FBAT), GJA4 (14 SNPs, 6 with p < 0.05), MEF2A (5 SNPs,
2 with p < 0.05), and PCSK9 (11 SNPs, 3 with p < 0.05).
For HF, 4 SNPs in PLN and 2 each in ADRB2 and TPM1
had p values < 0.05. There was little evidence of associa-
tion of AF with SNPs in specified candidate genes. Overall,
538 candidate-SNP association tests were carried out
because there were 130 SNPs common to both major
CHD and major CVD. Results with GEE p < 0.05 were
obtained for 28 tests (5.2%) and p < 0.01 for 5 tests
(0.9%), similar to the overall distribution in Table 3. Lack
of consistency between GEE and FBAT results may be due
to lower power of FBAT compared with GEE tests.
Additionally, we examined all association results for
major CHD and major CVD in the region of chromosome
9 that was recently reported to be associated with MI and
CHD [22,23], We found that 7 SNPs in a 76 Kb region had
p < 10-5 for one or both outcomes.
Discussion
Cardiovascular disease is the leading cause of death in
industrialized countries and will soon be the leading
cause of death in the developing world [24]. Genome-
wide association studies provide an opportunity to extend
our understanding of CVD pathogenesis and improve
public health. The identification of novel genes and path-
ways that play a causal role in CVD is an essential objec-
tive for the development of new therapies for the
prevention and treatment of CVD. Finding genetic associ-
ations with CVD risk that are robust across multiple stud-
ies will aid in the personalization of medicine by
identifying high risk individuals who can be targeted for
early and aggressive preventive care.
We provide results of genome-wide association for 4 CVD
outcomes of great public health impact: major CVD,
major CHD, AF, and HF. No associations attained
genome-wide significance [4.4 × 10-8 = 0.05/(70,987 SNPs
× 4 major traits × 2 adjustment levels × 2 association mod-
els)] in our analyses using GEE or FBAT additive genetic
models. With dramatic declines in the cost of high
throughput genotyping, selective genotyping of SNPs with
suggestive evidence of association can be considered.
Two-stage approaches – genome-wide association fol-
lowed by selective genotyping – have been adopted as a
practical and efficient strategy for pursuing initial
genome-wide results [25,26].
Results of GEE and FBAT associations pointed to few can-
didate genes of obvious interest for any CVD outcomes.
One intriguing result was the association of RYR2
(rs939698, p = 3.6 × 10-4) with HF. The ryanodine recep-
tor has been implicated in arrhythmogenic right ventricu-
lar dysplasia/cardiomyopathy [21,27], a rare familial
cardiomyopathy.
The lowest p values we identified may be purely by
chance. The number of events (maximum of 142 for
major CVD) was small to detect association, but would be
sufficient to detect a SNP with high minor allele frequency
in linkage disequilibrium with a causal variant that con-
tributed high risk. This was the case for a genome-wide
association study of age-related macular degeneration –
only 96 cases and 50 controls were sufficient to identify
genome-wide association with complement factor H [28].
Sometimes multiple SNPs in the same chromosomal
region had low GEE p values for a trait; for example, Table
2a has SNP clusters on chromosomes 6, 9, 11, 13, 15 and
17. Linkage disequilibrium exists for those clustered SNPs
(typically, pair-wise r2 above 0.80) and it is uncertain
Table 3: Distribution of Observed and Expected P Values from GEE models
P value group Frequency Percent Expected* Ratio**
0.10 ≤ p 254,464 89.6164 90.000% 1.00
0.01 ≤ p < 0.10 26,218 9.2334 9.000% 1.03
0.001 ≤ p < 0.01 2,892 1.0185 0.900% 1.13
0.0001 ≤ p < 0.001 337 0.1187 0.090% 1.32
0.00001 ≤ p < 0.0001 31 0.0109 0.009% 1.21
p < 0.00001 6 0.0021 0.001% 2.11
*Expected under uniform distribution. **Ratio of observed to expected.Page 5 of 9
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Candidate gene Total number of SNPs* SNPs with p value < 0.05 Phenotype GEE p value FBAT p value
Major CVD/Major CHD
ALOX5 5 0
ALOX5AP 23 rs7983138 Major CHD 0.011 0.373
rs2985183 Major CHD 0.014 0.455
rs7984952 Major CHD 0.015 0.266
rs117395 Major CHD 0.016 0.568
rs4603405 Major CHD 0.018 0.257
rs10507391 Major CHD 0.028 0.660
rs10507391 Major CVD 0.043 0.878
rs7995384 Major CHD 0.049 0.967
GJA4 14 rs618675 Major CHD 0.004 0.169
rs10489658 Major CHD 0.004 0.145
rs618675 Major CVD 0.009 0.464
rs10493062 Major CHD 0.011 0.051
rs768586 Major CHD 0.016 0.135
rs10489658 Major CVD 0.025 0.237
rs10489656 Major CHD 0.520 0.030
rs10489656 Major CVD 0.538 0.044
rs2093185 Major CVD 0.547 0.019
rs6686484 Major CHD 1.000 0.031
LGALS2 1 0
LTA 2 0
LTA4H 22 rs10492225 Major CHD 0.013 0.080
MEF2A 5 rs2033546 Major CVD 0.004 0.006
rs2863274 Major CVD 0.006 0.006
rs2033546 Major CHD 0.016 0.013
rs2863274 Major CHD 0.062 0.021
MMP3 17 rs2096767 Major CVD 0.028 0.506
rs2096767 Major CHD 0.032 0.610
rs566125 Major CVD 0.042 0.079
SERPINE1 2 0
PCSK9 11 rs2114580 Major CHD 0.010 0.075
rs2114580 Major CVD 0.026 0.057
rs2317951 Major CVD 0.076 0.002
rs2317951 Major CHD 0.077 0.002
rs2317948 Major CHD 0.478 0.029
rs2317948 Major CVD 0.584 0.026
THBS2 7 rs911839 Major CVD 0.192 0.035
rs911839 Major CHD 0.255 0.032
THBS4 16 rs264986 Major CHD 0.443 0.048
VAMP8 5 0
Atrial fibrillation
ACE 3 0
AGT 13 rs758216 0.041 0.204
GJA5 13 0
KCNE2 14 0
KCNH2 6 0
KCNJ2 23 rs10512574 0.140 0.041
KCNQ1 5 rs10488674 0.136 0.046
KCNE1 20 rs7277304 0.745 0.047
rs9305551 0.119 0.018
Heart failure
ABCC9 8 0
ACTC 15 rs752876 0.065 0.040Page 6 of 9
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related chance findings or indicate regions of heightened
interest.
Candidate gene results for the 4 CVD outcomes provided
suggestive confirmation of prior associations reported for
ALOX5AP (23 SNPs, 7 with p < 0.05 by GEE or FBAT),
GJA4 (14 SNPs, 6 with p < 0.05), MEF2A (5 SNPs, 2 with
p < 0.05), and PCSK9 (11 SNPs, 3 with p < 0.05) in rela-
tion to CHD risk. In contrast, candidate gene results for
HF and AF provided little evidence of replication of previ-
ously reported associations. Null results of these associa-
tions may be due in part to poor coverage of the
candidates by the SNPs on the 100K chip and the modest
number of events available for analysis. Our results can be
compared with other genome-wide associations of similar
phenotypes. We observed strong association of major
CVD with 3 SNPs in the region of chromosome 9 that was
recently reported to be associated with MI and CHD in
multiple samples [22,23]. This provides convincing evi-
dence that, despite modest numbers of events, we were
able to identify true associations.
This investigation has several limitations. This study used
CVD cases that were identified through careful surveil-
lance of a community-based sample with multigenera-
tional participation. Recruitment of original and offspring
cohort participants began long before DNA collection,
which occurred in recent years. Thus, most CVD cases
were prevalent at the time of DNA collection. For CVD
outcomes (such as these) with substantial mortality risk, a
survival bias may have been introduced by this study
design; individuals with early CVD events had to survive
and attend a later clinic examination at which DNA was
collected. Another limitation is the modest number of
events included in analyses, in particular for HF, where
only 73 events were available for analysis. For continuous
traits, we had 78% power to detect a SNP with QTL herit-
ability of 1% at significance level 10-3, and at significance
level 10-6 we had 84% power for QTL heritability 2% [20].
In the setting of a limited number of outcome events,
those are large effect sizes. The negative results of candi-
date gene analyses may underestimate associations for
genes that are incompletely covered by the SNPs used in
this investigation. Lastly, a large proportion of the results
are likely to be due to chance. Replication studies are
needed to determine which, if any, of the results we report
are indicative of true associations of causal variants with
disease outcomes.
ADRB1 12 0
ADRB2 18 rs40949 0.545 0.025
rs185021 0.947 0.040
ADRBK1 0 -
ATP2A2 3 0
CALML3 2 0
CTF1 0 -
DES 2 0
DSP 15 rs10484326 0.671 0.029
LDB3 0 -
LMNA 5 0
MYBPC3 4 0
MYH6 1 0
MYH7 2 0
MYL2 3 0
MYL3 1 0
PLN 16 rs3951042 0.025 0.083
rs724868 0.055 0.039
rs9320660 0.063 0.034
rs10484286 0.074 0.043
SGCD 37 0
TNNC1 4 rs1133415 0.040 0.131
TNNI3 1 0
TNNT2 9 rs832177 0.015 0.164
TPM1 7 rs10519186 0.011 0.085
rs902027 0.152 0.011
TTN 13 rs10497521 0.705 0.030
VCL 3 0
*Includes all SNPs within 200 kb upstream of start to 200 kb downstream of end of gene, with genotype call rate ≥0.8; minor allele frequency ≥0.1; 
HWE p ≥ 0.001.
Data are sorted by GEE additive genetic effects model with FBAT results provided alongside.
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BMC Medical Genetics 2007, 8(Suppl 1):S5 http://www.biomedcentral.com/1471-2350/8/S1/S5These association results for major CVD outcomes extend
experience with genome-wide association studies. Repli-
cation studies are needed and will be used to guide future
genotyping and resequencing efforts. Finding genetic var-
iants associated with CVD may facilitate the identification
of high risk patients and aid in identifying targeted future
approaches to prevention and treatment of CVD.
Abbreviations
AF = atrial fibrillation; CHD = coronary heart disease; HF
= heart failure; CVD = cardiovascular disease; FBAT = fam-
ily based association test; GEE = generalized estimating
equation.
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